Patents Assigned to Ganymed Pharmaceuticals, AG
-
Patent number: 8765389Abstract: The invention relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for said products. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors and to the coding nucleic acids for said proteins, polypeptides and peptides.Type: GrantFiled: September 10, 2004Date of Patent: July 1, 2014Assignee: Ganymed Pharmaceuticals AGInventors: Öezlem Tüereci, Ugur Sahin, Michael Koslowski
-
Publication number: 20140127219Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.Type: ApplicationFiled: April 20, 2012Publication date: May 8, 2014Applicants: JOHANNES GUTENBERG-UNIVERSITÄT MAINZ, GANYMED PHARMACEUTICALS AGInventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Korden Walter, Stefan Wöll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan, Michael Weichel
-
Patent number: 8716455Abstract: The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which said genetic products that are expressed in association with a tumor are expressed in an aberrant manner. The invention also relates to proteins, polypeptides, and peptides which are expressed in association with a tumor and the nucleic acids coding therefor.Type: GrantFiled: August 25, 2008Date of Patent: May 6, 2014Assignee: Ganymed Pharmaceuticals AGInventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
-
Patent number: 8637012Abstract: The invention relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the invention also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.Type: GrantFiled: November 15, 2011Date of Patent: January 28, 2014Assignee: Ganymed Pharmaceuticals AGInventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
-
Patent number: 8551490Abstract: The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which the genetic products that are expressed in association with a tumor are expressed in an aberrant manner. The invention also relates to proteins, polypeptides, and peptides which are expressed in association with a tumor and the nucleic acids coding therefor.Type: GrantFiled: July 18, 2011Date of Patent: October 8, 2013Assignee: Ganymed Pharmaceuticals AGInventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
-
Patent number: 8529904Abstract: A peptide comprising the amino acid sequence RMFPNAPYL or a portion or variant thereof provided that the peptide is not intact human WT-1 polypeptide or a peptide comprising the amino acid sequence CMTWNQMNL or a portion or variant thereof provided that the peptide is not intact human WT-1 polypeptide or a peptide comprising the amino acid sequence HLMPFPGPLL or a portion or variant thereof provided that the peptide is not intact human gata-1 polypeptide, and polynucleotides encoding these peptides. The peptides and polynucleotides are useful as cancer vaccines.Type: GrantFiled: July 6, 2007Date of Patent: September 10, 2013Assignee: Ganymed Pharmaceuticals AGInventors: Hans Josef Stauss, Liquan Gao
-
Patent number: 8425902Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, cancer of the gallbladder, and the metastases thereof.Type: GrantFiled: May 27, 2008Date of Patent: April 23, 2013Assignees: Ganymed Pharmaceuticals AG, Johannes Gutenberg-UniversitatInventors: Ugur Sahin, Ozlem Tureci, Gunda Brandenburg, Dirk Usener
-
Patent number: 8399210Abstract: According to the invention, autoantibodies, the appearance of which is characteristic of neurological autoimmune diseases, especially multiple sclerosis, are detected and the respective autoantigens identified. It can further be shown that many of these autoantigens are expressed specifically in the brain. The identification of the autoantigens and autoantibodies is useful for diagnosis and treatment. A brain-specific expression of the autoantigens further emphasizes an important role of the antigens and antibodies in the origin and development of neurological autoimmune diseases.Type: GrantFiled: April 8, 2009Date of Patent: March 19, 2013Assignees: Ganymed Pharmaceuticals AG, Johannes Gutenberg-UniversitatInventors: Ugur Sahin, Özlem Türeci, Alexander Zaigler
-
Patent number: 8354104Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, and hepatocellular cancer.Type: GrantFiled: March 14, 2008Date of Patent: January 15, 2013Assignees: Ganymed Pharmaceuticals AG, Johannes Gutenberg—UniversitatInventors: Ugur Sahin, Michael Koslowski, Ozlem Tureci
-
Publication number: 20120258091Abstract: The invention relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the invention also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.Type: ApplicationFiled: November 15, 2011Publication date: October 11, 2012Applicant: GANYMED PHARMACEUTICALS AGInventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
-
Publication number: 20120195830Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.Type: ApplicationFiled: March 21, 2012Publication date: August 2, 2012Applicants: JOHANNES GUTENBERG-UNIVERSITAT MAINZ, GANYMED PHARMACEUTICALS AGInventors: Ugur Sahin, Özlem Türeci, Dirk Usener, Stefan Fritz, Christoph Uherek, Gunda Brandenburg, Harald-Gerhard Geppert, Anja Kristina Schröder, Phillippe Thiel
-
Publication number: 20120164160Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD1 8, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.Type: ApplicationFiled: November 29, 2011Publication date: June 28, 2012Applicants: JOHANNES GUTENBERG-UNIVERSITAT MAINZ, GANYMED PHARMACEUTICALS AGInventors: Ugur Sahin, Özlem Türeci, Dirk Usener, Stefan Fritz, Christoph Uherek, Gunda Brandenburg, Harald-Gerhard Geppert, Anja Kristina Schröder, Phillippe Thiel
-
Publication number: 20120165390Abstract: The present invention is directed to siRNA molecules which specifically target and cause RNAi-induced degradation of mRNA from TPTE genes, so that the protein product of the TPTE gene is not produced or is produced in reduced amounts. The siRNA compounds and compositions of the invention are useful for treating diseases which require inhibition of TPTE expression for their treatment, in particular cancer pathologies. The present invention also includes methods which make possible to assess and/or prognose the metastatic behaviour of a cancer disease and/or the occurrence of a relapse of cancer.Type: ApplicationFiled: November 21, 2011Publication date: June 28, 2012Applicants: JOHANNES GUTENBERG-UNIVERSITAT MAINZ, GANYMED PHARMACEUTICALS AGInventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
-
Patent number: 8168427Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.Type: GrantFiled: November 24, 2006Date of Patent: May 1, 2012Assignees: Ganymed Pharmaceuticals AG, Johannes Gutenberg-Universitat MainzInventors: Ugur Sahin, Ozlem Tureci, Dirk Usener, Stefan Fritz, Cristoph Uherek, Gunda Brandenburg, Harald-Gerhard Geppert, Anja Kristina Schroder, Philippe Thiel
-
Patent number: 8088588Abstract: The invention relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the invention also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.Type: GrantFiled: December 3, 2008Date of Patent: January 3, 2012Assignee: Ganymed Pharmaceuticals AGInventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
-
Patent number: 8088913Abstract: The present invention is directed to siRNA molecules which specifically target and cause RNAi-induced degradation of mRNA from TPTE genes, so that the protein product of the TPTE gene is not produced or is produced in reduced amounts. The siRNA compounds and compositions of the invention are useful for treating diseases which require inhibition of TPTE expression for their treatment, in particular cancer pathologies. The present invention also includes methods which make possible to assess and/or prognose the metastatic behavior of a cancer disease and/or the occurrence of a relapse of cancer.Type: GrantFiled: December 7, 2006Date of Patent: January 3, 2012Assignees: Ganymed Pharmaceuticals AG, Johannes Gutenberg-Universitat MainzInventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
-
Publication number: 20110135640Abstract: The present invention provides agents with tumor-inhibiting activity, and which are selective for cells expressing or abnormally expressing a tumor-associated antigen. Said tumor-associated antigen has a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence selected from the specific sequences set forth herein, or a 6-50 contiguous nucleotide residue portion thereof; (b) a nucleotide sequence of a nucleic acid which hybridizes with a nucleic acid having the nucleotide sequence of (a) under stringent conditions; (c) a nucleotide sequence which is degenerate with respect to the nucleotide sequence of (a) or (b); and (d) a nucleotide sequence which is complementary to the nucleotide sequence of (a), (b) or (c). Pharmaceutical compositions and kits comprising the agents are also provided, as well as methods treating, diagnosing or monitoring a disease characterized by expression or abnormal expression of the tumor-associated antigen.Type: ApplicationFiled: December 16, 2010Publication date: June 9, 2011Applicant: GANYMED PHARMACEUTICALS AGInventors: ÖZLEM TÜRECI, UGUR SAHIN, GERD HELFTENBEIN, VOLKER SCHLÜTER
-
Patent number: 7875424Abstract: According to the invention, tumour-associated gene products and nucleic acids coding therefor were identified. The present invention relates to the therapy and diagnosis of diseases wherein said tumour-associated gene products are expressed aberrantly. The invention also relates to proteins, polypeptides and peptides which are expressed in a tumour-associated manner and the nucleic acids coding therefor.Type: GrantFiled: September 23, 2004Date of Patent: January 25, 2011Assignee: Ganymed Pharmaceuticals, AGInventors: Özlem Türeci, Ugur Sahin, Gerd Helftenbein, Volker Schlüter
-
Publication number: 20110014628Abstract: An isolated truncated desmoglein 4 (DSG4) polypeptide splice variant of the invention is characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75. Also disclosed is a method of diagnosing a cancer, or monitoring the course thereof, in a patient. The method comprises detecting in a tissue sample of a patient the expression of a tumor-associated antigen comprising the extracellular domain of a DSG4 polypeptide encoded by a DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75, or a truncated DSG4 polypeptide splice variant characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene.Type: ApplicationFiled: August 6, 2010Publication date: January 20, 2011Applicant: GANYMED PHARMACEUTICALS, AGInventors: Özlem TÜRECI, Ugur SAHIN, Sandra SCHNEIDER, Gerd HELFTENBEIN, Volker SCHLÜTER, Dirk USENER, Philippe THIEL, Michael KOSLOWSKI
-
Patent number: 7785801Abstract: The invention relates to the identification of gene products that are the result of tumor-associated expression and the nucleic acids encoding the same. The invention also relates to the therapy and diagnosis of diseases wherein these gene products are the result of an aberrant tumor-associated expression. The invention also relates to the proteins, polypeptides and peptides that are the result of tumor-associated expression and to the nucleic acids encoding the same.Type: GrantFiled: May 11, 2005Date of Patent: August 31, 2010Assignee: Ganymed Pharmaceuticals, AGInventors: Özlem Türeci, Ugur Sahin, Sandra Schneider, Gerd Helftenbein, Volker Schlüter, Dirk Usener, Philippe Thiel, Michael Koslowski